Shares of Novartis AG (VTX:NOVN) have received an average rating of “Hold” from the fifteen analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is CHF 84.60.
Several brokerages have recently issued reports on NOVN. HSBC Holdings plc set a CHF 85 target price on shares of Novartis AG and gave the stock a “buy” rating in a report on Wednesday, June 21st. Barclays PLC set a CHF 65 target price on shares of Novartis AG and gave the stock a “sell” rating in a report on Friday, June 2nd. Goldman Sachs Group, Inc. (The) set a CHF 80 target price on shares of Novartis AG and gave the stock a “neutral” rating in a report on Friday, July 14th. Berenberg Bank set a CHF 85 target price on shares of Novartis AG and gave the stock a “neutral” rating in a report on Friday, July 14th. Finally, JPMorgan Chase & Co. set a CHF 75 target price on shares of Novartis AG and gave the stock a “neutral” rating in a report on Wednesday, July 19th.
Novartis AG (VTX NOVN) opened at 79.90 on Friday. The stock has a 50 day moving average of CHK 80.97 and a 200-day moving average of CHK 77.44. The firm has a market cap of CHK 187.20 billion and a P/E ratio of 29.17. Novartis AG has a 12 month low of CHK 67.40 and a 12 month high of CHK 84.35.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2017/08/12/novartis-ag-novn-given-consensus-rating-of-hold-by-analysts.html.
Novartis AG Company Profile
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
What are top analysts saying about Novartis AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novartis AG and related companies.